Medicus Pharma (NASDAQ:MDCX) Releases Quarterly Earnings Results, Misses Estimates By $0.07 EPS

Medicus Pharma (NASDAQ:MDCX) released its earnings results on Wednesday. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.07), Zacks reports.

Medicus Pharma Stock Down 4.3%

MDCX opened at $0.33 on Thursday. Medicus Pharma has a 52-week low of $0.25 and a 52-week high of $3.05. The company has a 50 day moving average of $0.37 and a two-hundred day moving average of $0.55. The company has a market cap of $18.76 million, a P/E ratio of -0.12 and a beta of 0.11.

Analyst Ratings Changes

Several equities analysts recently commented on the stock. Alliance Global Partners began coverage on shares of Medicus Pharma in a research report on Tuesday, July 28th. They set a “buy” rating for the company. D. Boral Capital reissued a “buy” rating and set a $9.00 price objective on shares of Medicus Pharma in a research note on Monday, April 20th. Roth Capital assumed coverage on Medicus Pharma in a report on Tuesday, April 21st. They set a “buy” rating for the company. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Medicus Pharma in a research report on Wednesday, July 8th. Three analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $9.00.

Institutional Trading of Medicus Pharma

Institutional investors have recently added to or reduced their stakes in the business. Armistice Capital LLC acquired a new position in shares of Medicus Pharma during the fourth quarter worth about $2,771,000. Jane Street Group LLC acquired a new stake in shares of Medicus Pharma in the fourth quarter valued at about $92,000. HRT Financial LP purchased a new stake in shares of Medicus Pharma during the 4th quarter valued at about $42,000. Wilmington Savings Fund Society FSB raised its holdings in shares of Medicus Pharma by 100.0% during the 4th quarter. Wilmington Savings Fund Society FSB now owns 51,244 shares of the company’s stock valued at $78,000 after buying an additional 25,622 shares during the period. Finally, Commonwealth Equity Services LLC lifted its position in Medicus Pharma by 161.8% during the 4th quarter. Commonwealth Equity Services LLC now owns 28,493 shares of the company’s stock worth $44,000 after acquiring an additional 17,611 shares in the last quarter.

About Medicus Pharma

Medicus Pharma, Inc, traded on the Nasdaq under the ticker MDCX, is a specialty pharmaceutical company focused on the development, acquisition and commercialization of prescription therapies. The company’s core business centers on oncology supportive care and critical care products, with its lead offering being Levoleucovorin injection, an FDA-approved agent designed to reduce toxicity and enhance efficacy of certain chemotherapeutic regimens in colorectal cancer.

Headquartered in the United States, Medicus Pharma has built its portfolio through strategic licensing and acquisition of sterile injectable and oral therapies.